Abivax SA (2X1.SG)
| Previous Close | 12.86 |
| Open | 12.86 |
| Bid | 12.80 x 0 |
| Ask | 13.04 x 0 |
| Day's Range | 12.78 - 12.96 |
| 52 Week Range | 7.80 - 19.16 |
| Volume | |
| Avg. Volume | 49 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Apr 02, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ACCESSWIREAbivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn’s and Colitis Organization (ECCO)
PARIS, FRANCE / ACCESSWIRE / February 13, 2024 / Abivax SA (Euronext Paris:ABVX))(NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms ...
- ACCESSWIRE
Abivax Announces Closing of its Initial Public Offering on the Nasdaq Global Market
PARIS, FRANCE / ACCESSWIRE / October 24, 2023 / Abivax SA (Euronext Paris:FR0012333284 - ABVX) (" Abivax " or the " Company "), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms ...
- ACCESSWIRE
Abivax Announces Trading Resumption of its Ordinary Shares on Euronext Paris
PARIS, FRANCE / ACCESSWIRE / October 20, 2023 / Abivax SA (Euronext Paris:FR0012333284 - ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms ...
